Hormone-free option
Safety focused
Women’s Health Clinic FAQ
Are polynucleotides effective for GSM and vaginal atrophy?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
Polynucleotides may support hydration, collagen and tissue-repair signalling in selected patients with GSM or vulvovaginal atrophy, especially when used in PN/HA formulations. Evidence is encouraging but still developing, so the treatment should be framed as an assessment-led option rather than a promised reversal of atrophy. GSM can involve dryness, burning, painful sex and urinary symptoms, and established care such as moisturisers, lubricants and local vaginal ooestrogen may still be relevant.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Mechanism of Action
PNs release nitrogen precursors that stimulate fibroblast proliferation, promote angiogenesis, and create a hydrating gel matrix within the extracellular space.
Delivery Methods
Treatments are administered via daily intravaginal ovules, topical creams, or intradermal clinical injections (frequently combined with hyaluronic acid, such as.
Key Benefits
noticeably reduces severe vaginal dryness, dyspareunia (painful intercourse), burning, and itching , .
Clinical Outcomes
Restores a healthy, acidic vaginal pH and may improve the Vaginal Health Index (VHI) and Vulvar Health Index (VuHI).
Important safety note
PN/HA treatments are generally described as well tolerated in selected studies, but infection, bleeding, allergy history and medical suitability still need screening.
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Evidence for GSM and atrophy
PN/HA data is relevant to vulvovaginal atrophy, but treatment should still be framed as developing evidence.
GSM is a diagnosis, not a sales term
The strongest page explains low-ooestrogen tissue change, established care and where PN might fit as an adjunct.
Evidence
Symptoms
Alternatives
What it means
Focus on the Comfort Layer: PNs target the superficial mucosal and vestibular layers to improve hydration, elasticity, and comfort, rather than providing deep structural support , .
Why symptoms matter
Not a Mechanical resolve: While they heal micro-tears and improve glide, they do not mechanically "tighten" the vaginal canal or correct anatomical defects like pelvic organ prolapse , .
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
At-Home Therapies: PN-based ovules and creams are Class III medical devices intended for daily self-administration at home, typically over a 2 to 4 week cycle , .
What this means in practice
At-Home Therapies: PN-based ovules and creams are Class III medical devices intended for daily self-administration at home, typically over a 2 to 4 week cycle , .
Onset of Action: Patients using PN-based ovules or creams often report significant symptom relief (like reduced dryness and burning) within the first two weeks of use , .
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Focus on the Comfort Layer: PNs target the superficial mucosal and vestibular layers to improve hydration, elasticity, and comfort, rather than providing deep structural.
It protects safety
Safety depends on choosing the right patient, excluding red flags and giving clear aftercare before treatment starts.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Initial Assessment: The journey begins with a thorough medical consultation to rule out red flags (e.g., unexplained bleeding, active infections) and optimise foundational care like pelvic floor therapy.
During care
Treatment Selection: Based on symptoms and medical history (e.g., hormone contraindications), the clinician and patient select the appropriate PN delivery method (ovule, cream, or injection) .
Aftercare
Administration: The patient undergoes the clinical injection series or completes the at-home topical cycle as prescribed , .
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Onset of Action: Patients using PN-based ovules or creams often report significant symptom relief (like reduced dryness and burning) within the first two weeks of use , .
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments used for gradual tissue-quality support, not instant volume.
Myth: hormone-free means suitable for everyone
Reality: fish allergy, infection, bleeding, pregnancy, recent surgery and unclear pain can make treatment unsuitable.
Myth: results are promised
Reality: response varies and should be reviewed before repeating treatment.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
PubMed: PN/HA intradermal treatment for vulvovaginal atrophy
This pilot study is directly relevant to PN/HA use in vulvovaginal atrophy and supports cautious evidence-aware discussion.
NICE menopause recommendations
NICE provides UK guidance for GSM, vaginal ooestrogen, non-hormonal care and cancer-history decision-making.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 69 imported records. Additional reviewed material included peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
